[
  {
    "ts": null,
    "headline": "RCUS Stock Down on Decision to Discontinue GILD Partnered Study",
    "summary": "Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.",
    "url": "https://finnhub.io/api/news?id=d52e3898f39a05cb95aa072f3f996c731666165cd4ebd6ea74aeeffe68fab117",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765810740,
      "headline": "RCUS Stock Down on Decision to Discontinue GILD Partnered Study",
      "id": 137795434,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.",
      "url": "https://finnhub.io/api/news?id=d52e3898f39a05cb95aa072f3f996c731666165cd4ebd6ea74aeeffe68fab117"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial",
    "summary": "FOSTER CITY, Calif., December 15, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically no",
    "url": "https://finnhub.io/api/news?id=d0008ebe8cd9e02d46428d20af39bf77fbd0dfc16129b2f7dfceca50b848c612",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765805400,
      "headline": "Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial",
      "id": 137792582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., December 15, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically no",
      "url": "https://finnhub.io/api/news?id=d0008ebe8cd9e02d46428d20af39bf77fbd0dfc16129b2f7dfceca50b848c612"
    }
  }
]